---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 21, 2008 at 12:14 AM
Subject: Bayer Schering/Onyx: Nexavar suffers setback in lung cancer (Pharmaceutical Business Review)
To: mesothelioma77@gmail.com
Disappointing Phase III data presents a considerable blow to Nexavars prospects of expansion into the potentially lucrative indication of non-small-cell lung cancer. While development of the drug is likely to continue in this indication, the negative trial results and inevitable delay to market could prove costly.
Thu, 21 Feb 2008 02:32:16 GMT
___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=13fbccvd0/*http%3A//www.pharmaceutical-business-review.com/article_feature.asp?guid=6F287202-8739-4ABF-8F7F-50DB314E0BA4
--
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Thu, Feb 21, 2008 at 12:14 AM
Subject: Bayer Schering/Onyx: Nexavar suffers setback in lung cancer (Pharmaceutical Business Review)
To: mesothelioma77@gmail.com
Disappointing Phase III data presents a considerable blow to Nexavars prospects of expansion into the potentially lucrative indication of non-small-cell lung cancer. While development of the drug is likely to continue in this indication, the negative trial results and inevitable delay to market could prove costly.
Thu, 21 Feb 2008 02:32:16 GMT
___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=13fbccvd0/*http%3A//www.pharmaceutical-business-review.com/article_feature.asp?guid=6F287202-8739-4ABF-8F7F-50DB314E0BA4
--